tirzepatide nafld in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon? Tirzepatide (Zepbound)

A lean "after" photo usually reflects the diet and training run alongside the peptide, not the peptide alone

Thinking about its safety profile

Moreover, insulin does not appear to be associated with prostate cancer risk [4]

While some people notice changes in appetite within the first week, visible weight loss typically occurs more gradually

As a result, it remains active in the body for about a week (half-life ~7 days)

GLP-1 Agonists: Treatment Failure Does Not Preclude Prevention The November 2025 announcement from Novo Nordisk that oral semaglutide failed to slow Alzheimers progression in the EVOKE and EVOKE+ trials was widely reported as a setback